Project Grant R41HL180100
Award Date 8/10/26
Completion Date 7/31/28
Dollars Obligated $686K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48103, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded Starlight Cardiovascular, Inc. $499,952 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 10, 2026, to advance commercialization of a catheter-delivered, adjustable percutaneous pulmonary flow restrictor designed to replace surgical pulmonary artery banding in newborns with hypoplastic left heart syndrome and other congenital heart defects. The flow restrictor addresses clinical limitations of current surgical...
- The National Heart, Lung, and Blood Institute awarded New York University $331,344 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on heart donor selection and utilization. The research addresses two primary barriers limiting U.S. heart transplant volume: insufficient evidence on which donor risk factors impact outcomes, and difficulty synthesizing clinical data during donor selection. The study will investigate the impact of specific...
- The National Heart, Lung, and Blood Institute awarded Inflo Medical Inc. $595,332 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to optimize its MOBYBOX extracorporeal membrane oxygenation (ECMO) platform for pediatric use. Inflo Medical is redesigning the MOBYBOX's gas exchanger and pulsatile displacement pump to reduce thrombogenicity and hemolysis in pediatric patients. The Phase I Small Business Innovation Research effort focuses on two complementary...
- Federal Project Grant Award Summary Perfusion Solutions Inc. received a $320,838 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 5, 2025, with completion targeted for February 28, 2027. The award supports Phase I development of a fail-safe, high-output cavopulmonary assist pump designed for pediatric and congenital heart disease patients with single ventricle physiology...
- The National Heart, Lung, and Blood Institute awarded Perfusion Solutions Inc. $217,013 on August 1, 2026, to develop a bearingless, fail-safe pump for patients with single ventricle physiology following Fontan surgical palliation under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds Phase I research to design and develop a bearingless motor integrated into a centrifugal pump rotor, with the pump's stator incorporating the motor stator. The device is engineered to...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $1,574,578 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel targeted modified mRNA delivery strategies for donation after circulatory death (DCD) heart transplantation. The research addresses primary graft dysfunction (PGD), an ischemia-reperfusion injury occurring in approximately 35 percent of heart transplants and driven by hyper-inflammatory responses involving...
- The National Heart, Lung, and Blood Institute awarded Lazarus 3D, Inc. $400,016 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate PRE-SURE-CHD, a patient-specific preoperative surgical rehearsal and planning platform for congenital heart defects using 3D printing technology. The project develops synthetic materials that replicate the mechanical properties of cardiac tissue, creates patient-specific 3D-printed prototypes informed by CT...
- The National Heart, Lung, and Blood Institute awarded Medluidics LLC $227,639 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a cardiopulmonary unit-on-a-chip for investigating right ventricular hypertrophy caused by pulmonary arterial hypertension and for developing targeted treatments. The recipient will develop a microfluidic device that models both the right ventricle and pulmonary artery separated by a collagen layer, enabling culture of...
- The National Heart, Lung, and Blood Institute awarded Corvion, Inc. $2,999,968 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel pediatric left ventricular assist device (P-LVAD) enabling children with end-stage heart failure to discharge home while awaiting heart transplantation or living long-term with the device. This is a Project Grant (SBIR Phase II). Corvion will engineer an implantable, ultra-low-power blood pump combining hydrodynamic...